Overview

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of MEDI-545 in subjects with moderately to severely active Lupus.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
Sifalimumab